Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=095d8b2c-b123-4f1f-80f2-b5236e50f898&Preview=1
Date 4/15/2009
Company Name Synageva BioPharma Corp
Mailing Address 60 Hickory Drive Waltham, MA 02451
Company Description Synageva BioPharma’s ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva’s proprietary platform technologies, including SEPTM, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Our platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics.
Proceeds Purposes This funding will be utilized to advance Synageva’s products to later stages of development in order to maximize their value for partnership discussions.
